

Visionary AI: Decoding Systemic Vascular Health and Hypertensive Disorders in Pregnancy Through Retinal Imaging and Artificial Intelligence

Authors: Srilaxmi Bearely^{1,2,*}, Cassandra Areff³, Matthew K. Hoffman⁴, Daniel Sunko³, Andrew F. Laine^{5,6,7}, Bin Choi³, Hanna Rodriguez Coleman¹, Bianca Cordazzo Vargas³, Chloe Y. Li¹, Jennifer Dawkins³, Emily Amir^{1,2}, Lisa A. Hark¹, Whitney A. Booker², April Jauhal³, Ronald J. Wapner², Liat Shenhav^{3,8,9,10,*}

¹ Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, USA

² Department of Obstetrics & Gynecology, Columbia University Irving Medical Center, New York, NY, USA

³ Institute for Systems Genetics, NYU Grossman School of Medicine, New York University, New York, NY, USA

⁴ Division of Obstetrics & Gynecology, ChristianaCare, Newark, DE, USA

⁵ Department of Biomedical Engineering, Columbia University, New York, NY, USA

⁶ Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA

⁷ Center for Health Analytics, Data Science Institute, Columbia University, New York, NY, USA

⁸ Department of Microbiology, NYU Grossman School of Medicine, New York University, New York, NY, USA

⁹ Department of Obstetrics & Gynecology, NYU Grossman School of Medicine, New York University, New York, NY, USA

¹⁰ Department of Computer Science, Courant Institute of Mathematical Sciences, New York University, New York, NY, USA

* Corresponding authors: Srilaxmi Bearely sb3179@cumc.columbia.edu; Liat Shenhav

liat.shenhav@nyulangone.org

Abstract

1 Pregnancy orchestrates a rare physiological transformation across vascular, immune, and
2 metabolic systems. When this dynamic balance is disrupted – as in hypertensive disorders of
3 pregnancy – the consequences can be life-threatening, spanning maternal mortality, fetal
4 growth restriction, and elevated long-term cardiovascular risk. Despite clear links to early
5 placental dysfunction and systemic endothelial disruption, current screening remains clinically
6 imprecise, biologically opaque, and logistically challenging. A shift is urgently needed – from
7 detecting maternal complications late in gestation to understanding how pregnancy reshapes
8 vascular physiology systemically and how this remodeling may go awry.

9 Here we present Visionary AI, an artificial intelligence platform that integrates ultra-widefield
10 retinal imaging (200°) with biologically grounded vascular modeling to predict hypertensive
11 disorders of pregnancy early in gestation. Unlike prior approaches that rely on generic deep
12 learning models and clinical inputs, Visionary AI constructs an interpretable, graph-based
13 representation of the maternal retinal vasculature and applies topological and geometric
14 analysis to identify condition-specific microvascular signatures. In a prospective multiethnic U.S.
15 cohort of 1,267 pregnancies, Visionary AI achieved high predictive performance for
16 preeclampsia (AUC = 0.90), early-onset (AUC = 0.93), and severe preeclampsia (AUC = 0.89),
17 outperforming current clinical paradigms. It also generalized to predict gestational hypertension
18 (AUC = 0.91) and chronic hypertension (AUC = 0.90).

19 Topological and geometric analyses of the vasculature revealed distinct and interpretable
20 remodeling patterns across subtypes of hypertensive disorders of pregnancy, offering
21 mechanistic insight into their divergent pathophysiology.

22 These results position the maternal retina as a minimally invasive, high-fidelity biosensor of
23 early systemic vascular health and establish Visionary AI as a clinically actionable, biologically
24 grounded diagnostic framework with potential for broad global scalability.

25

26 **Introduction**

27 ***Hypertensive Disorders of Pregnancy***

28 Hypertensive disorders of pregnancy (HDP), including gestational hypertension (GHTN),
29 preeclampsia, chronic hypertension with superimposed preeclampsia, and eclampsia, affect 2–
30 15% of pregnancies and represent the second leading cause of maternal mortality worldwide¹.
31 HDPs increase the risk of acute maternal complications such as renal dysfunction, pulmonary
32 edema, stroke, and death², and contribute to adverse fetal outcomes, including small-for-
33 gestational-age, preterm delivery, and stillbirth³. Long-term, they are associated with elevated
34 maternal risk of hypertension, coronary artery disease, stroke, and vascular dementia^{4–6}, and
35 elevated offspring risk of cardiovascular and neurodevelopmental disorders⁷.

36 Despite their burden, HDPs are typically diagnosed after 20 weeks' gestation, when symptoms
37 such as hypertension, proteinuria, or organ dysfunction become clinically apparent. Severe
38 features – including blood pressure (BP) >160/110 mmHg, thrombocytopenia, and visual
39 symptoms – guide early delivery decisions due to high maternal–fetal risk⁸. Early-onset
40 preeclampsia (EOPE, symptoms appear before 34 weeks) tends to present more severe
41 complications than late-onset preeclampsia (LOPE). Notably, recent systems biology studies
42 suggest that preeclampsia is not a single disease entity but may reflect multiple distinct
43 biological pathways – with EOPE more frequently associated to placental dysfunction and LOPE
44 more often associated with maternal processes^{9,10}.

45 ***Pathophysiology and Prevention***

46 Mechanistically, preeclampsia is believed to arise, in part, from maternal vascular inflammation
47 and thrombosis that disrupt placental development^{9,11}. Inflammation and thrombosis are known
48 to inhibit deep placental invasion¹² of the maternal decidua between 10 and 16 weeks' gestation
49 and then further impair the placenta resulting in placental atherosclerosis^{13,14,15,16}, a process very
50 similar to cardiovascular disease. These early deviations from physiologic placentation precede
51 clinical symptoms by weeks or months, underscoring the need for early biomarkers of systemic
52 and placental vascular stress.

53 From a health systems perspective, HDPs accounted for an estimated \$2.18 billion in U.S.
54 healthcare costs per year (estimated in 2012), largely driven by preterm birth complications¹⁷.
55 Their incidence has increased in subsequent years^{18,19,20}, and pregnancies complicated by
56 HDPs typically end ~3 weeks earlier than normotensive pregnancies²¹. Importantly, randomized
57 trials show that early initiation of low-dose aspirin (before 16 weeks) can reduce risk of preterm
58 preeclampsia by up to 62%^{22,23} – but this requires early, accurate risk identification.

59 ***Limitations of Current Screening***

60 Current diagnostic criteria for HDPs rely on late-onset symptoms (hypertension, proteinuria,
61 end-organ dysfunction), usually manifesting in the third trimester²⁴. While known risk factors
62 (e.g., prior HDPs, diabetes, obesity, age) provide some predictive value, they lack individual-
63 level accuracy²⁵. The sFlt-1/PIGF ratio is the most validated biomarker but is only useful after 20
64 weeks and in symptomatic patients²⁶. First-trimester screening tools, such as the Fetal Medicine
65 Foundation calculator²⁷, combine clinical variables with biomarkers or ultrasound, but these
66 protocols are expensive, logistically complex, and inconsistently implemented^{28,29}.

67 Taken together, these gaps underscore the need for a non-invasive, cost-effective, and scalable
68 screening tool that enables accurate risk prediction in the first trimester, prior to symptom onset,
69 and is suitable for broad population-level deployment.

70 ***Retinal Vascular Biomarkers of Hypertensive Disorders of Pregnancy***

71 Increasing evidence suggests a link between placental vascular changes associated with
72 preeclampsia and alterations in the retinal vasculature. Studies of women with established
73 preeclampsia describe retinal signs resembling hypertensive retinopathy, arteriolar narrowing,
74 and choroidal changes^{30–34}, and link preeclampsia to increased future risk of retinal diseases³⁵.
75 Further, recent evidence has identified an association between the sFlt-1/PIGF ratio and
76 choroidal thickness as measured by optical coherence tomography (OCT)^{33,36}. A prior
77 postpartum study from our team (31 severe preeclampsia cases and 35 normotensive controls)
78 demonstrated significantly increased median tortuosity in the inferotemporal retinal artery
79 among preeclampsia patients³⁷. OCT angiography (OCT-A) has revealed that pregnant women
80 who go on to develop placental insufficiency have significantly narrower retinal blood vessels
81 (arterioles and venules) compared to normotensive pregnancies³⁸. These patients also exhibit
82 reduced capillary density. In separate studies, women with preeclampsia had significantly lower
83 vessel densities in both the superficial and deep capillary plexuses – including in the foveal and
84 parafoveal regions – relative to healthy pregnant or non-pregnant controls^{39,40}. These findings
85 suggest a degree of capillary dropout or “vascular rarefaction” in the retinas of women with
86 preeclampsia. Notably, such changes are often subclinical. Retinal vessel caliber reduction and
87 reduced perfusion density likely result from systemic vasoconstriction and endothelial
88 dysfunction, both hallmarks of preeclampsia pathophysiology. Importantly, these changes may
89 be subclinical and observable even in early pregnancy, mirroring processes of endothelial
90 dysfunction and systemic vasoconstriction.

91 ***AI-Powered Retinal Imaging for Pregnancy Risk Stratification***

92 Retinal imaging offers a scalable, non-invasive method for systemic vascular phenotyping.
93 Ultra-widefield (UWF) systems can capture ~200° of the retina in under 2 minutes without pupil
94 dilation, making them highly deployable in prenatal care. Prior studies have shown that AI

95 models trained on retinal images can accurately predict demographic and clinical parameters
96 such as age, sex, and hemoglobin levels, as well as future risk of systemic diseases including
97 diabetes, stroke, and cardiovascular disease^{41–44}.

98 Initial efforts to apply AI to HDP prediction via retinal imaging have been promising but limited.
99 The PROMPT model (Preeclampsia Risk factor + Ophthalmic data + Mean arterial pressure
100 Prediction Test)⁴⁵ relied heavily on clinical variables (e.g., MAP) and achieved modest image-
101 only performance (AUC ~0.6). Another study combining 45-degree retinal fundus images with
102 clinical data reported improved accuracy, but used a convolutional neural network architecture
103 that lacks interpretability and biological insight⁴⁶. Notably, both studies were conducted in
104 homogenous East Asian populations, further limiting their generalizability and translational
105 impact.

106 ***Visionary AI: A Mechanistically Grounded, Interpretable Framework for Risk Screening***

107 Here we introduce *Visionary AI*, an end-to-end computational framework that takes as input
108 ultra-widefield retinal images and predicts an individual’s risk of hypertensive disorders of
109 pregnancy. Unlike prior approaches that treat retinal images as opaque inputs to generic deep
110 learning models, Visionary AI represents a fundamentally different approach: it models the
111 retinal vasculature as a quantifiable, interpretable biological system – one that mirrors systemic
112 endothelial and angiogenic processes occurring during placental development.

113 We show across a cohort of 1,267 pregnant participants that this framework enables accurate
114 and interpretable prediction of preeclampsia and gestational hypertension months before clinical
115 diagnosis. Our results demonstrate that the maternal retina can serve as a proxy biosensor for
116 systemic vascular health in pregnancy – opening a new frontier in non-invasive, biologically
117 grounded, and globally scalable obstetric risk stratification.

118 **Results**

119 ***Cohort Characteristics and Study Design***

120 A total of 1,267 pregnant individuals that attended their prenatal visits between the years of
121 2021 and 2025 at the New York-Presbyterian Hospital (Columbia University Medical Center)
122 were recruited for this study. Within this cohort, 55 (4.3%) participants were diagnosed with
123 preeclampsia, which was defined and diagnosed using the 2013 ACOG Guidelines⁸.

124 Participants with preeclampsia were further stratified based on disease severity, with 38 (3.0%)
125 classified as “with severe features” (SF), and 17 (1.3%) classified as “without severe features”
126 (NSF). Additionally, 20 (1.6%) were classified as EOPE, while the remaining 35 (2.8%) were
127 classified as LOPE. All cases were independently reviewed twice (maternal-fetal medicine
128 specialists WB, and EA) both of whom were masked to the retinal imaging results. One

129 participant was excluded from the retinal analysis due to poor image quality, reducing the
130 preeclampsia, NSF, and LOPE case counts by one.

131 **Table S1** summarizes the demographic and clinical characteristics of the study population.
132 Clinical data collected included maternal age, race/ethnicity, tobacco use, prior pregnancy
133 history, pre-existing conditions, and medication use. We also recorded pregnancy-related
134 complications (e.g., gestational hypertension, gestational diabetes), and birth outcomes,
135 including small for gestational age (SGA, <10th percentile), severe SGA (<3rd percentile),
136 stillbirth, birth weight, and Apgar scores. Notably, 85% of participants self-identified as Hispanic
137 or Latinx. There were no significant differences between participants who developed
138 preeclampsia and those who did not in terms of maternal age, race/ethnicity, obesity status, or
139 tobacco use. However, individuals who developed preeclampsia were significantly more likely to
140 have a history of preeclampsia in prior pregnancies (16.4% vs. 3.8%; $p = 4.1e-05$, Chi-square
141 test) and to have pre-existing hypertension (18.2% vs. 3.5%; $p = 5.5e-07$, Chi-square
142 test). Additionally, participants who developed gestational hypertension had significantly higher rates
143 of obesity compared to normotensive population-wide controls (65% vs. 33%; $p = 6.5e-06$, Chi-
144 square test).

145 Retinal images were acquired using the Optos SLO Primary fundus camera during the first (6–
146 13 gestational weeks, GW), second (14–27 GW), and third (28–40 GW or until delivery)
147 trimesters. **Figure 1** provides an overview of the study design and the Visionary AI
148 computational framework, including the sample collection timeline, central hypothesis, and
149 model architecture.

150 ***The Visionary AI Framework***

151 Visionary AI is an end-to-end computational framework that takes as input ultra-widefield retinal
152 images and predicts an individual's risk of hypertensive disorders of pregnancy, including
153 preeclampsia (as defined in the ACOG guidelines), EOPE, LOPE and gestational hypertension.
154 The pipeline begins with the generation of vessel segmentation images (VSIs) using a bespoke
155 version of the retinal vessel generative adversarial network (RV-GAN)⁴⁷. The model was initially
156 trained on external datasets containing fundus images (45 degrees) and hand annotated VSIs
157 to establish baseline performance^{48–52}. The model was then fine-tuned using high-quality,
158 ultrawide-field segmentation maps curated from retinal images of participants in our cohort.
159 These maps were manually annotated and validated by a retinal specialist, ensuring both
160 accuracy and clinical reliability (see Methods for details). For visits with multiple images per eye,
161 VSIs were merged to create a single coherent representation per eye, accounting for variation in
162 gaze and image acquisition. This fusion was performed in two steps: (1) feature-based
163 homography to achieve coarse alignment of the VSIs, addressing global shifts in positioning,
164 and (2) deformable image registration to correct local non-linear distortions in vascular

165 geometry. The latter step was critical for aligning vessel structures that appeared warped or
166 spatially inconsistent across frames, enabling anatomically faithful composite VSIs suitable for
167 downstream risk prediction.

168 The merged VSIs were transformed into graph-based representations to enable vascular
169 feature extraction. In this representation, nodes were assigned to vessel branch points and
170 terminations, with edges connecting adjacent nodes to form a vessel network. From these
171 graphs, structural features – such as node degree (e.g., number of branches per bifurcation),
172 total number of nodes, and branching complexity – were computed. In parallel, geometric
173 features, such as vessel tortuosity, curvature, and loop complexity, were derived either from the
174 graph or directly from the binary VSI. To capture higher-order vascular topology, we applied
175 topological data analysis (TDA): retinal vessel pixels were subsampled and processed to
176 generate persistence images, which encode topological features such as connected
177 components and loops across scales. Additionally, higher order features were extracted by
178 analyzing the hierarchical structure of the loops in the vasculature of the retina⁵³. All extracted
179 features were subsequently grouped into semantically related feature sets. Each set was then
180 used to train an independent classifier (base learner). These predictors serve as building blocks
181 for the final ensemble model. We evaluated three classification algorithms as base learners:
182 Logistic Regression (LR), Random Forest (RF), and XGBoost (XGB). Each model was trained
183 independently on individual feature sets derived from the VSIs, with hyperparameters tuned
184 separately for each feature set–classifier pair. These base learners were then integrated using a
185 stacked generalization framework, wherein their out-of-fold predictions served as inputs to a
186 XGBoost meta-learner with recursive feature elimination, which generated the final risk
187 prediction. Both base learners and the meta-learner were trained using leave-one-out cross-
188 validation (LOOCV), a strategy selected to optimize data utilization in the context of our
189 prospective study design and the low incidence of preeclampsia and other HDPs. LOOCV
190 minimizes overfitting and yields robust, unbiased performance estimates, particularly important
191 for rare outcome prediction^{54,55}.


192

193

194

195

196



197
 198 **Figure 1. Study and Algorithm Design** (A) A timeline of the study procedure. Participants were
 199 approached for retinal imaging in the first, second, and third trimesters. Prediction of preeclampsia was
 200 done utilizing the first trimester images, except for participants that lacked these images, in which case
 201 second trimester images were used. Clinical preeclampsia diagnosis was given after week 20 of gestation.
 202 Preeclampsia cases are considered early-onset if the diagnosis occurred before week 34, and late onset if
 203 it occurred after week 34. (B) The primary hypothesis of the study is that it is possible to accurately
 204 predict the risk of developing preeclampsia using first trimester retinal images. (C) Our computational
 205 pipeline can be broadly divided into three modules. I. Image processing: fundus images are collected for
 206 both eyes for a given participant. VSIs are generated for each image. Images for the same eye are merged
 207 to create a more complete VSI. II. Feature generation: the VSI are used to generate informative features
 208 related to the vascular structure of the retina. III. Predictive model: we utilize an ensemble model
 209 architecture which uses base learners to make individual predictions based on groups of features. These
 210 predictions are aggregated using a stacking meta-learner to make a final prediction. *PEC* (preeclampsia);
 211 *VSIs* (vessel segmentation images).

212 **Prediction of Preeclampsia from Retinal Features**

213 Visionary AI demonstrated high predictive performance using retinal images obtained in early
 214 pregnancy, achieving an achieving an area under the receiver operating characteristic curve
 215 (AUC) of 0.94, average precision (AP) of 0.92, and a positive predictive value (PPV) of 0.85 in
 216 distinguishing individuals who subsequently developed preeclampsia (n = 54) from healthy

217 controls (n = 82; **Figure S1**). The healthy controls were defined as study participants without
218 any background medical conditions or pregnancy complications. Specifically, the healthy control
219 group excluded individuals with maternal comorbidities, pregnancy complications, or ocular
220 conditions – including cardiometabolic, neurologic, vascular, hematologic, endocrine, infectious,
221 or genetic diseases – as well as those with multifetal gestation, prior ocular surgery or trauma,
222 medication use (e.g., antihypertensives, insulin, aspirin), or pregnancies affected by
223 hypertensive disorders, gestational diabetes, cholestasis, hyperemesis, stillbirth, multiple
224 gestation, or smoking (see Methods for details). This set of 82 healthy controls was selected
225 from a larger group of 176 healthy controls in the cohort to maintain class balance for model
226 training and to enable approximate case-control matching on key demographic and imaging
227 variables.

228 To evaluate the generalizability and clinical utility of our approach, we next assessed its
229 performance in predicting preeclampsia among a broader, population-wide group of non-cases
230 (n = 1,083) – more reflective of real-world obstetric populations than the rigorously defined
231 healthy control subset. In this expanded cohort, we relaxed exclusion criteria to omit only
232 multiple pregnancies (e.g., twins/triplets) and/or pregnancies ending in stillbirth, thereby
233 including individuals with common comorbidities such as pre-existing hypertension, diabetes,
234 and obesity. This allowed us to test model performance in a clinically heterogeneous setting.

235 Using bootstrapped subsets (10 iterations, $n_i \geq 100$), Visionary AI maintained strong predictive
236 accuracy, achieving a mean AUC of 0.90 ± 0.06 , AP of 0.76 ± 0.11 , and PPV of 0.79 at a 0.5
237 threshold (**Figure 2AB**). These results demonstrate that model performance generalizes
238 beyond highly selected populations, retaining predictive power even in the presence of
239 comorbidities that can influence retinal morphology. The modest decline in performance
240 compared to the healthy control group likely reflects increased biological and imaging
241 heterogeneity in the population-wide cohort. Adding clinical variables to the model via an
242 additional base learner did not significantly improve predictive performance (AUC = 0.90 ± 0.06 ;
243 AP = 0.78 ± 0.10 ; PPV = 0.79), suggesting that the retinal imaging features alone capture most
244 of the signal relevant to preeclampsia risk. While clinical data may offer complementary insights,
245 they appear to contribute minimally beyond what is already captured by the retinal vasculature.

246 ***Prediction of Preeclampsia subtypes from Retinal Features***


247 We further evaluated the performance of the model within clinically relevant subtypes of
248 preeclampsia to ensure that overall accuracy was not driven by a single subgroup. Specifically,
249 we assessed model performance separately for preeclampsia with severe features (SF; n = 38)
250 and without severe features (NSF; n = 16). NSF was defined as new-onset hypertension after
251 20 weeks of gestation ($\geq 140/90$ mmHg on two occasions, at least 4 hours apart) accompanied
252 by either proteinuria or mild signs of maternal organ dysfunction (e.g., mild thrombocytopenia,

253 mildly elevated liver enzymes, or renal impairment not meeting severe thresholds)⁸. SF met the
254 same diagnostic criteria but included at least one severe complication – such as systolic BP
255 ≥ 160 mmHg, diastolic BP ≥ 110 mmHg, thrombocytopenia, elevated liver enzymes, renal
256 insufficiency, pulmonary edema, or new-onset neurological symptoms⁸.

257 Despite the small sample sizes, Visionary AI maintained strong predictive performance for both
258 subtypes: SF cases were predicted with an AUC of 0.89 ± 0.06 , AP of 0.71 ± 0.13 , and PPV of
259 0.72 , while NSF cases achieved an AUC of 0.92 ± 0.06 , AP of 0.57 ± 0.20 , and PPV of 0.55 .
260 These findings confirm that Visionary AI can accurately predict both preeclampsia subtypes,
261 while maintaining comparable predictive performance when the groups are analyzed together.

262 We further applied a subgroup analysis to examine the ability of Visionary AI to predict early-
263 (EOPE: $n = 20$) and late-(LOPE: $n = 34$) onsets of preeclampsia. These subtypes are clinically
264 defined by the timing of diagnosis – EOPE occurring at or before 34 weeks of gestation, and
265 LOPE after 34 weeks. Emerging evidence suggests that EOPE and LOPE may arise from
266 partially distinct biological mechanisms, with a stronger association between LOPE and
267 maternal cardiovascular or metabolic risk factors and EOPE more associated with placental
268 processes^{9,10}. The EOPE subset was predicted with an AUC of 0.93 ± 0.07 , AP of 0.64 ± 0.15 ,
269 and a PPV of 0.61 , while LOPE was predicted with an AUC of 0.88 ± 0.06 , AP of 0.67 ± 0.15 ,
270 and a PPV of 0.69 , indicating high performance even when evaluating more heterogeneous
271 clinical presentations.

272 As with overall preeclampsia prediction, the inclusion of clinical features provided only marginal
273 gains in model performance across subtypes, indicating that the retinal vasculature alone
274 captures the dominant predictive signal (SF: AUC = 0.89 ± 0.06 , AP = 0.73 ± 0.12 , PPV = 0.72 ;
275 NSF: AUC = 0.92 ± 0.06 , AP = 0.60 ± 0.19 , PPV = 0.55 ; EOPE: AUC = 0.92 ± 0.06 , AP = 0.64
276 ± 0.16 , PPV = 0.60 ; LOPE: AUC = 0.89 ± 0.05 , AP = 0.71 ± 0.12 , PPV = 0.70).



277

278 **Figure 2. Visionary AI performance predicting preeclampsia with Population-Wide Controls (A)**
 279 ROC curves, PR curves, and retinal model SHAP distributions by category and key base learners for
 280 different preeclampsia subgroups. The retinal model outperforms the clinical model in all cases. The all
 281 model, which combines both retinal and clinical features performs the best. (B) ROC along with average
 282 Precision (PPV), NPV, and TPR values are shown for retinal model in barplots with a threshold of 0.5.
 283 FPR for all subsets of 0.06. (C) SHAP values for key feature categories and base learners, labeled with

284 relevant biological processes. *PEC* (preeclampsia); *SF* (severe features); *NSF* (no severe features);
285 *EOPE* (early onset preeclampsia); *LOPE* (late onset preeclampsia).

286 **Benchmarking with Existing Risk Models for Preeclampsia**

287 To evaluate the added predictive value of retinal imaging, we benchmarked the performance of
288 Visionary AI using retinal features alone against models trained on clinical features alone, which
289 reflect current approaches to preeclampsia risk assessment. We included a variety of clinical
290 factors encompassing both demographics and relevant diagnostic history, including age and
291 prior adverse pregnancy outcomes such as preeclampsia and gestational diabetes,
292 representing a modified version of the Fetal Medicine Foundation (FMF) preeclampsia risk
293 assessment model⁵⁶. Several FMF variables – such as maternal height, weight, last menstrual
294 period, and portions of maternal medical history – were unavailable in our dataset (see Methods
295 for details).

296 To ensure comparability, we used the same model architecture (evaluating LR, RF, and XGB)
297 for both the FMF clinical-only and retinal-only models. This approach isolates the impact of
298 feature type – clinical vs. retinal – on model performance. The clinical-only model showed
299 limited predictive ability in distinguishing cases from population-wide controls across
300 preeclampsia subtypes (preeclampsia: AUC = 0.65 ± 0.03 , AP = 0.46 ± 0.06 , PPV = 0.50; SF:
301 AUC = 0.68 ± 0.03 , AP = 0.45 ± 0.07 , PPV = 0.44; NSF: AUC = 0.59 ± 0.04 , AP = 0.15 ± 0.06 ,
302 PPV = 0.18; EOPE: AUC = 0.67 ± 0.05 , AP = 0.29 ± 0.09 , PPV = 0.30; LOPE: AUC = 0.64 ± 0.02 ,
303 AP = 0.37 ± 0.07 , PPV = 0.37). In contrast, and as reported above, the retinal-only model
304 performed substantially better across all preeclampsia subtypes (preeclampsia: AUC = $0.90 \pm$
305 0.06 , AP = 0.76 ± 0.11 , PPV = 0.79; SF: AUC = 0.89 ± 0.06 , AP = 0.71 ± 0.13 , PPV = 0.72; NSF:
306 AUC = 0.92 ± 0.06 , AP = 0.57 ± 0.20 , PPV = 0.55; EOPE: AUC = 0.93 ± 0.07 , AP = 0.64 ± 0.15 ,
307 PPV = 0.61; LOPE: AUC = 0.88 ± 0.06 , AP = 0.67 ± 0.15 , PPV = 0.69), and adding clinical
308 features yielded minimal performance gains. This suggests that the retinal signal captured by
309 Visionary AI already encompasses much of the predictive information provided by the clinical
310 features.

311 At fixed false positive rates (FPRs) of 5%, 10%, and 15%, Visionary AI achieved substantially
312 higher true positive rates (TPRs) and positive predictive values (PPVs) than those reported for
313 the PROMPT model⁴⁵, which used narrower-field RetiCam3100 fundus imaging (~135 degrees)
314 and incorporated maternal risk factors, mean arterial pressure (MAP), and the retinal image.
315 Specifically, Visionary AI yielded TPRs and PPVs of 0.68 and 0.80 (5% FPR), 0.79 and 0.71
316 (10% FPR), and 0.84 and 0.65 (15% FPR). In comparison, PROMPT reported markedly lower
317 TPRs and PPVs of 47.7 and 32.3, 60.5 and 23.1, and 72.1 and 19.3, respectively, at the same
318 FPR thresholds.

319 It is important to note that this is not a direct, head-to-head comparison – our analysis did not
320 use the PROMPT model or its dataset, as neither the code nor data are publicly available.
321 These findings suggest that Visionary AI may offer markedly improved sensitivity and precision,
322 even under strict false positive constraints, and further underscore its potential as a robust,
323 clinically actionable tool for early detection of hypertensive disorders of pregnancy.

324 ***Topological and Geometric Features Reflect Early Vascular Stress in Pregnancy***


325 To interpret our model predictions using the vascular alterations preceding preeclampsia, we
326 analyzed the vascular features extracted by the VSI pipeline. We employed both model-
327 independent univariate analyses and model-derived Shapley Additive Explanation (SHAP)
328 values⁵⁷ (**Figure 2C**) to assess feature importance. The features that most consistently
329 differentiated preeclampsia and its subtypes from both healthy and population-wide controls
330 clustered into four distinct categories: (i) graph-topology (e.g., counts of vessel tips, branches,
331 topological length), (ii) geometry (e.g., tortuosity, vessel caliber/thickness), (iii)
332 complexity/organization captured by topological data analysis and box counting fractal analysis
333 (e.g., outward radial filtrations), and (iv) nesting-tree metrics that summarize the hierarchical
334 organization of loops and bifurcations (e.g., loops, asymmetry). **Figure 3** provides examples of
335 vascular features that are differentially distributed across these broad categories, illustrates
336 them graphically, and links each feature category to underlying biological processes.

337 ***Univariate Analyses Reveal Early Microvascular Remodeling in Preeclampsia***

338 Graph-topology features capture the vasculature's connectivity (e.g., counts of vessel tips and
339 branches, and inter-branch distances) from its graph representation. In our cohort, the number
340 of branches was lower in preeclampsia than in healthy controls ($p = 0.04$, Mann–Whitney U,
341 Figure 3A); potentially suggesting a reduced branch-initiation rate in preeclampsia. Inter-branch
342 distances can be influenced both by branching and by tip extension (greater extension without
343 new bifurcations tends to increase distances, whereas new branches tend to reduce them). To
344 capture these processes jointly, we examined topological length, defined for each node as the
345 maximum number of edges to any terminal (tip), which reflects hierarchical depth. In the inferior
346 retina, preeclampsia cases showed a greater mean distance from both healthy and population-
347 wide controls in the distribution of weighted topological length ($p = 0.02$ and 0.01 respectively,
348 Mann–Whitney U; weighted by vessel width). Taken together, these observations suggest that
349 preeclampsia may involve alterations in both branch initiation and vessel extension, with
350 topological length providing a scale-free summary of their combined effects^{58,59}.

351 Geometric features describe the shape, curvature, and caliber of retinal vessels, reflecting how
352 efficiently blood is distributed across the vascular network. Among these, the most informative
353 are tortuosity and vessel thickness. Tortuosity metrics quantify the extent of vessel curvature,

354 winding, and twisting, capturing deviations from a straight path that can signal vascular stress or
 355 remodeling. We found that squared curvature tortuosity was significantly greater in samples
 356 from participants with preeclampsia and preeclampsia with SF compared to healthy controls (p
 357 = 0.01 for both, Mann–Whitney U test). However, this signal was attenuated when compared to
 358 the broader population-wide control group due to greater variability within that group. Increased
 359 tortuosity reflects enhanced vessel curvature and is often associated with altered vessel
 360 maturity, oxidative stress, and hemodynamic stress^{45,60–63}. Vessel thickness, representing flow
 361 capacity, was computed as the average vessel width (see Methods for details). We observed a
 362 significant change in the distributions of vessel thickness in the superior retina of preeclampsia
 363 for SF cases compared with healthy controls ($p = 0.04$, Mann–Whitney U test).



364 **Figure 3.** Preeclampsia-associated features reflect clinically relevant biological vessel properties. Each
 365 column reflects a feature class used to construct base learners for the ensemble model. For each class, **(A)**
 366 boxplots depicting the distributional differences between preeclampsia cases, healthy and population-
 367 wide controls across a few notable retinal features/categories, **(B)** a cartoon highlighting the differential
 368 signals captured in feature calculations within each category, and **(C)** the main relevant angiogenesis-

369 related processes are depicted. Branch count reflects the number of branch nodes (marked with black
370 circles in B). Topological length reflects the number of nodes between the root and the tip averaged over
371 all branches. Tortuosity reflects the ratio between the linear distance and total vessel distance. The
372 number of loops is a count of the loops in the vascular network. The outward radial TDA filtration
373 captures the emergence and disappearance of connected components and loops as the vascular network is
374 reconstructed outward from the optic disc. *PEC (preeclampsia); HC (healthy controls); PW (population-*
375 *wide controls)*. Comparisons tested using Mann-Whitney U test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

376

377 To capture the network-level organization of the retinal vasculature, we quantified a set of
378 complexity features summarizing global geometric and topological structure – including box-
379 counting fractal analysis, TDA, and nesting tree metrics. These complementary approaches
380 describe how vessels are spatially arranged, connected, and hierarchically branched across
381 scales, providing a quantitative window into vascular integrity and remodeling. Box-counting
382 complexity measures the fractal organization of the vascular tree and reflects how efficiently
383 vessels occupy space. We observed a significant difference in the box counting distributional
384 pattern in the preeclampsia group compared to both healthy and population-wide controls ($p =$
385 0.002 and $p = 7.04e-06$ respectively, Mann–Whitney U), suggesting a simpler, less space-filling
386 vessel network consistent with microvascular loss or pruning. Notably, previous studies have
387 also reported lower retinal fractal dimensions in women diagnosed with preeclampsia, so it is
388 possible that we are capturing an early deviation⁶⁴.

389 The outward radial TDA filtration captures the emergence and disappearance of connected
390 components and loops as the vascular network is reconstructed outward from the optic disc. At
391 small radii, only central trunk vessels are present; as the radius expands, peripheral branches
392 and loops sequentially appear. This analysis summarizes central-to-peripheral vascular
393 organization, and it revealed highly significant alterations in preeclampsia compared with both
394 healthy and population-wide controls ($p = 0.01$ and $p = 0.02$ respectively, Mann–Whitney U).
395 Biologically, both altered box-counting distributions and the abnormal TDA profile point to
396 greater vascular disorganization in women with preeclampsia compared to healthy controls.
397 Effective vascularization requires that vessel tips initiate at correct sites and subsequently
398 migrate toward areas of greatest hypoxia to ensure uniform tissue perfusion^{65,66}. This requires
399 spatial gradients of pro and anti-angiogenic signals which, if not properly coordinated, could
400 result in the disorganization seen in the preeclampsia patients. Coordinated pro- and anti-
401 angiogenic signals are required to ensure that tips form and elongate in the regions they are
402 most needed to ensure even coverage and prevent gaps or excessively overlapping vessels
403 which alter the higher-order structure of the vessel architecture^{67–69,45,70}. Disruption of these
404 signals – as has been implicated in preeclampsia pathogenesis – could underlie the pronounced
405 retinal vascular disorganization we quantified in early pregnancy.

406 The nesting tree framework further describes the hierarchical loop structure of the vasculature
407 (following Katifori et al.⁵³). Two key features – loop count and asymmetry – were significantly
408 altered in preeclampsia eyes. We observed a reduction in the number of loops compared to
409 healthy controls ($p = 0.03$ Mann–Whitney U) alongside a shift in asymmetry distribution in
410 preeclampsia compared with population-wide controls ($p = 0.006$, Mann–Whitney U), potentially
411 indicating a more tree-like and less redundant vessel network. Biologically, asymmetry
412 quantifies how balanced the branching architecture is: lower asymmetry (a highly connected,
413 “multiplicative” network with many loops) supports alternative flow routes and greater resilience
414 to vessel occlusion, whereas higher asymmetry (an “additive,” tree-like structure) indicates
415 vulnerability – where the loss of a main branch can disproportionately impair perfusion. The
416 increase in asymmetry and loss of loops in preeclampsia retinas aligns with microvascular
417 rarefaction and pruning observed in systemic hypertension and placental ischemia^{71–74},
418 reflecting a shift toward a less adaptive vascular topology. For example, mid-pregnancy
419 evaluations of systemic microcirculation have shown that reduced capillary density (structural
420 rarefaction) independently predicts later preeclampsia, underscoring a pathologic loss of
421 microvascular channels⁷⁵. Our retinal findings mirror this phenomenon in the eye, with a sparser
422 vascular network and the removal of looped collateral paths.

423 Of note, at the univariate level, EOPE cases had a different complexity and nesting tree profile
424 that made it distinct from controls and from LOPE. For example, box counting distribution was
425 significantly altered compared to both healthy and population-wide controls ($p = 1e-4$ and $p =$
426 $2.8e-06$ respectively, Mann–Whitney U, **Figure S4**), as well as compared to LOPE ($p = 0.006$,
427 Mann–Whitney U). EOPE cases also had a significant reduction in the number of loops
428 compared with both healthy and population-wide controls ($p = 0.004$ and $p = 0.016$ respectively,
429 Mann–Whitney U). EOPE had a distinct ratio of weighted topological length in the superior
430 retina to inferior retina compared to both healthy and population-wide controls ($p = 0.02$ and $p =$
431 0.01 respectively, Mann–Whitney U), as well as compared to LOPE ($p = 0.02$, Mann–Whitney
432 U). This topological length signal is also present in the form of an altered distribution in the
433 weighted topological length in the inferior retina compared to both healthy and population-wide
434 controls ($p = 0.03$ and $p = 0.02$ respectively, Mann–Whitney U). These findings support the
435 hypothesis – commonly suggested in the literature⁹ – that EOPE and LOPE may involve
436 partially distinct biological mechanisms. While both conditions share clinical features, our results
437 align with prior work suggesting that EOPE and LOPE may reflect divergent pathophysiological
438 trajectories. Nonetheless, we can accurately predict both conditions using the Visionary AI
439 approach.

440 ***SHAP and Univariate Analyses Patterns Converge on Key Vascular Signatures***

441 Graph-topology base learners exhibited the highest average absolute SHAP values when
442 distinguishing preeclampsia from both healthy and population-wide controls, followed by
443 complexity features for population-wide controls and nesting tree features for healthy controls
444 (**Figures 2C & S2**). For population-wide controls, the most informative feature sets included
445 graph topology, box counting, and vessel branching angles. These findings are consistent with
446 univariate analyses showing that vessel extension, branch initiation, and vascular sparsity differ
447 significantly in preeclampsia.

448 Other important feature sets included geometric complexity, superior topological length shifts,
449 and tortuosity. In comparisons with healthy controls, nesting tree asymmetry (the ratio of
450 descendants on the left and right subtrees) emerged as a particularly informative signal,
451 highlighting the potential of asymmetric vascular architecture to distinguish preeclampsia from
452 healthy states (**Figure S3**).

453 Taken together, the consistent importance of graph-based, angle-based, and box counting
454 features across models and control groups underscores their robust predictive value. These
455 vascular signatures also align with known retinal changes observed later in pregnancy in
456 individuals with preeclampsia – including reduced vessel caliber and lower perfusion density –
457 features likely reflecting systemic vasoconstriction and endothelial dysfunction that restrict
458 microvascular blood flow. The ability of Visionary AI to detect these signatures early in
459 pregnancy underscores both its biological validity and its potential as a powerful screening tool.

460 ***Visionary AI Generalizability Across Gestational Hypertension and Pre-existing*** 461 ***Hypertension***

462 Finally, we evaluated the ability of the Visionary AI framework to predict additional hypertensive
463 disorders, specifically gestational hypertension and chronic (pre-existing) hypertension
464 diagnosed prior to pregnancy. Although both gestational hypertension and preeclampsia are
465 thought to originate in placental dysfunction⁷⁶, we hypothesized that they give rise to distinct
466 retinal vascular signatures detectable in first-trimester images. Specifically, we expect that
467 preeclampsia and gestational hypertension each produce unique patterns of microvascular
468 remodeling, with preeclampsia potentially exhibiting more spatially extensive alterations. These
469 clinical phenotypes also differ in their comorbidities: participants who developed gestational
470 hypertension had significantly higher rates of obesity (65% vs. 33%; $p = 6.5e-06$, Chi-square
471 test), while those who developed preeclampsia had higher rates of chronic hypertension (18.2%
472 vs. 3.5%; $p = 5.5e-07$, Chi-square test).

473 To this end, we used a similar model architecture to assess our approach's generalizability in
474 distinguishing gestational hypertension ($n = 49$) and chronic hypertension ($n = 61$, excluding
475 subjects with superimposed preeclampsia). These new models were able to predict GHTN with


476 an AUC of 0.91 ± 0.05 , AP of 0.81 ± 0.09 , and PPV of 0.81. CHTN with an AUC of 0.90 ± 0.06 ,
477 AP of 0.77 ± 0.13 , and PPV of 0.77.

478 At the univariate level, we observed a consistent reduction in vascular branch counts across all
479 hypertensive disorders evaluated – chronic hypertension, gestational hypertension, and
480 preeclampsia – relative to both healthy controls ($p = 7e-4, 0.02, 0.04$ respectively, Mann–Whitney
481 U) and population-wide controls ($p = 0.004$, Mann–Whitney U, chronic hypertension). Despite
482 this shared pattern, gestational hypertension and preeclampsia exhibited distinct topological
483 profiles. Specifically, in both gestational and chronic hypertension, the mean weighted nesting
484 ratio and nesting number were significantly reduced compared to healthy controls ($p = 0.001$,
485 0.001 and $p = 0.002, 0.005$, respectively, Mann–Whitney U) and to population-wide controls ($p =$
486 $0.009, 0.008$ and $p = 0.05, 0.06$, respectively, Mann–Whitney U), indicating a simplification of
487 hierarchical vascular organization. Furthermore, topological differences in Vietoris–Rips (VR)
488 filtrations were also significant in both gestational and chronic hypertension relative to healthy
489 controls ($p = 0.08$ and $p = 0.005$, Mann–Whitney U) and population-wide controls ($p = 0.02$ and
490 $p = 0.04$, Mann–Whitney U), with a larger effect size observed for chronic hypertension. This
491 suggests localized simplification of microvascular architecture and diminished hierarchical
492 complexity. These findings are consistent with subtle, spatially constrained changes in vessel
493 branching or spacing that may reflect impaired autoregulatory capacity or early microvascular
494 rarefaction.

495 The SHAP values for the GHTN and CHTN models align with the univariate results, with three
496 of the top five GHTN base learners and one of the top five CHTN base learners using the
497 nesting number feature set (**Figure S5 & S6**). The CHTN model differs from GHTN, similar to
498 the univariate results, with the Angles LR & RF as its top two base learners.

499 In contrast, preeclampsia was characterized by a broader pattern of global vascular remodeling.
500 Specifically, we found significant differences in TDA outward filtrations, consistent with
501 disruption of global vascular morphology and boundary organization. These changes were
502 accompanied by a reduced number of vascular loops, alterations in asymmetry and box-
503 counting metrics, and elevated tortuosity – collectively suggesting a loss of structural regularity
504 and potential disruption of bilateral and scale-invariant vascular organization.

505 Overall, our model demonstrates strong predictive performance for both conditions, supporting
506 the notion that retinal imaging can detect early, subclinical vascular changes in high-risk
507 pregnancies. The differences in retinal topology may reflect the divergent timing, severity, or
508 underlying mechanisms of these hypertensive disorders of pregnancy.



509

510 **Figure 4. (A-B)** ROC, PR curves, and SHAP values for prediction of gestational hypertension and
 511 chronic hypertension. The retinal model outperforms the clinical model in all cases. The combined model,
 512 which uses both retinal and clinical features performs the best for all conditions. **(C)** Boxplots depicting
 513 the distributional differences between gestational hypertension, chronic hypertension, healthy and
 514 population-wide controls across a few notable retinal features/categories. *HC (healthy controls); GHTN*
 515 *(gestational hypertension); PW (population-wide controls); CHTN (chronic hypertension)*. Comparisons
 516 tested using Mann-Whitney U test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

517

518 Discussion

519 **Early-Pregnancy Retinal Imaging Enables Pre-Symptomatic Prediction of Hypertension** 520 **Disorders of Pregnancy**

521 Visionary AI detects retinal vascular signatures of hypertensive disorders of pregnancy from
 522 ultra-widefield imaging, enabling prediction well before clinical symptoms emerge. By detecting
 523 subtle signs of placental maladaptation and systemic endothelial stress, Visionary AI offers a
 524 biologically grounded, interpretable, and scalable solution for early risk stratification across
 525 diverse obstetric populations.

526 Retinal images were acquired using a 200degree Optos ultra-widefield system, providing an
527 ~80% view of the retina and enabling detection of early microvascular perturbations that may
528 reflect placental dysfunction or systemic vascular stress. Within a prospective U.S. cohort of
529 1,267 pregnancies, Visionary AI achieved high predictive performance across preeclampsia
530 subtypes – AUC = 0.90 for preeclampsia, 0.93 for early onset preeclampsia, and 0.89 for
531 preeclampsia with severe features – substantially exceeding the performance of a first trimester
532 clinical only model (AUC = 0.65). The model also generalized to predict gestational
533 hypertension (AUC = 0.91) and chronic hypertension (AUC = 0.90), underscoring its broad
534 clinical relevance.

535 ***Interpretable Vascular Signatures Reflect Early Systemic Pathophysiology***

536 A key advance of Visionary AI is its interpretable framework. Rather than relying solely on deep
537 learning, the algorithm constructs a graph-based representation of the retinal vasculature and
538 extracts topological, geometric, and complexity-based features from vessel segmentation
539 images. These signatures consistently distinguished cases from both healthy and population
540 wide controls, with graph based, angle based, and box counting feature sets emerging as the
541 strongest contributors – patterns that align with the univariate analyses demonstrating
542 differences in vessel extension, branch initiation, and vascular sparsity.

543 These retinal signatures mirror hallmark pathology observed later in pregnancy across retinal
544 imaging studies^{40,75}, including reduced vessel density, lower perfusion, diminished branching
545 complexity, and increased vascular asymmetry. Such findings are thought to reflect a
546 combination of anti-angiogenic signaling, microvascular rarefaction, and altered vascular tone.
547 Notably, our model detected these signatures months before symptom onset – reinforcing their
548 biological grounding and supporting the concept of early systemic vascular remodeling in the
549 pathogenesis of HDPs.

550 ***“Simplified” Vasculature as a Systemic Hallmark of Preeclampsia***

551 Visionary AI captures early signs of vascular simplification, a hallmark of preeclampsia, driven
552 by two complementary pathological processes: capillary network rarefaction^{40,75} (loss of small
553 vessels, reduced density, and impaired branching complexity) and arteriolar wall thickening
554 (hypertrophic remodeling that narrows luminal diameter and increases resistance)⁷⁷. These
555 processes jointly contribute to reduced network redundancy, lower perfusion, and heightened
556 susceptibility to ischemic injury^{12,14,79}. Our topological metrics, including changes in loop
557 structure, asymmetry, and branching organization, reflect these early deviations from
558 physiologic vascular remodeling. Superior–inferior retinal differences in feature importance
559 further align with known variations in regional blood flow⁷⁸. That Visionary AI identifies these
560 shifts early in gestation underscores the system-wide vascular impairment characteristic of
561 HDPs and provides mechanistic insight into divergent early- and late-onset disease pathways.

562 ***Comparison to Prior AI Approaches***

563 While recent work has explored AI-based preeclampsia prediction using retinal imaging – most
564 notably the PROMPT model⁴⁵ – these models have shown modest performance (AUC ~0.6
565 using images alone), rely heavily on clinical variables (e.g., MAP), and were developed in
566 homogeneous East Asian cohorts. Visionary AI differs fundamentally in design and
567 performance: it requires no clinical inputs, is mechanistically interpretable, and achieves
568 substantially higher predictive accuracy in a racially and clinically diverse population.

569 At matched false positive rates (5%, 10%, 15%), Visionary AI consistently achieved higher true
570 positive rates and positive predictive values than PROMPT. This is not a head to head
571 comparison – PROMPT code and data are not publicly available – but the magnitude of
572 performance difference underscores the value of biologically informed vascular modeling
573 combined with ultra-widefield imaging.

574 ***Clinical Translation and Global Scalability***

575 Visionary AI offers a fast, noninvasive, and cost effective screening strategy suitable for both
576 high resource and low resource settings. Retinal fundus imaging requires no laboratory
577 infrastructure, takes less than two minutes to perform, and can be operated by nonspecialists.
578 As our computational pipeline is automated and does not require manual image grading, it
579 eliminates subjectivity and reduces implementation barriers.

580 This approach is particularly promising for low and middle income countries (LMICs), where cold
581 chain dependent biomarker assays and Doppler ultrasound are difficult to deploy at scale.
582 Retinal imaging – already widely used for diabetic retinopathy screening globally – could be
583 integrated into routine first trimester antenatal care to support early aspirin initiation, blood
584 pressure monitoring, and timely referral pathways.

585 ***Limitations and Future Directions***

586 Several limitations warrant consideration. Although our prospective cohort was large for imaging
587 based pregnancy research, the absolute number of early onset and severe preeclampsia cases
588 was modest due to low baseline prevalence. The single-site design limits demographic breadth
589 and calls for validation across diverse geographic and clinical settings. A higher-than-expected
590 proportion of severe cases likely reflects the underlying clinical population, and rigorous masked
591 review was performed to ensure accurate phenotyping.

592 Future and ongoing work includes multi-site international validation, integration with circulating
593 biomarkers and placental pathology for deeper mechanistic insight, and longitudinal imaging to
594 define dynamic vascular remodeling across gestation. These efforts are critical for realizing the
595 global potential of biologically interpretable AI to transform early pregnancy care and reduce
596 maternal morbidity worldwide.

597 **Methods**

598 This prospective study was approved by the Institutional Review Boards of Columbia University
599 and New York University and adhered to the tenets of the Declaration of Helsinki. Informed
600 consent was obtained from every participant prior to enrollment. The study aimed to capture
601 early retinal vascular signals in pregnancy among individuals receiving prenatal care at
602 Columbia University, with the goal of distinguishing those who would go on to develop HDP.

603 ***Cohort Description and Data Acquisition***

604 Pregnant individuals receiving routine prenatal care at the New York-Presbyterian Hospital at
605 Columbia University between 2021 and 2025 were enrolled in this study. Eligible participants
606 were ≥ 18 years of age and able to provide informed consent. Participants could be enrolled to
607 the study by the second trimester of pregnancy.

608 Maternal demographic and clinical data – including age, race/ethnicity, medical history, and
609 pregnancy-related diagnoses such as gestational diabetes mellitus (GDM) and hypertensive
610 disorders of pregnancy (HDPs), as well as laboratory values like hematocrit and hemoglobin
611 A1c – were extracted from the electronic health record. Delivery outcomes, including small for
612 gestational age (SGA), stillbirth (SB), birth weight, and Apgar scores, were also recorded.
613 Diagnoses were made by participants' obstetric clinicians during routine prenatal care and
614 cases were subsequently reviewed twice in masked fashion (WB and EA).

615 Retinal images were obtained for each eye by trained research technicians during the first (6–13
616 weeks), second (14–27 weeks), and third (28–40 weeks or until delivery) trimesters using the
617 Optos UWF Primary scanning laser ophthalmoscope, which captures ultra-widefield images
618 (200-degree field of view, covering over 80% of the retina). History of ocular conditions and
619 surgery was also captured and used for inclusion and exclusion criteria. This study focused on
620 prediction of hypertensive disorders early in pregnancy. First trimester images were used when
621 they were available, otherwise second trimester images were used (32% of preeclampsia, 24%
622 of gestational hypertension, 38% of cardiac hypertension, 43% of healthy controls, and 40% of
623 population-wide control participants). However, even second trimester images were obtained
624 before week 20 of gestation.

625 ***Image Preprocessing and AI-Generation of Vessel Segmentation Images***

626 We analyzed a total of 3,909 retinal images. Images were rescaled to a uniform zoom level and
627 resized to a standard resolution of 912 × 912 pixels. To minimize interference with downstream
628 processing, each image was cropped using a standardized elliptical mask to remove non-retinal
629 artifacts, such as eyelashes or peripheral obstructions outside the field of view. This process is
630 done by applying a uniform and programmatic cropping method.

631 Vessel segmentation images (VSI) were generated from these cropped fundus images using a
632 dedicated AI model designed for retinal vessel segmentation, inspired by generative adversarial
633 networks (RV-GAN)⁴⁷. The architecture includes a U-Net generator that learns both the overall
634 vessel structure and fine details. The model was trained on standard 45 degree color fundus
635 photographs paired with expert-annotated VSIs from publicly available datasets⁴⁸⁻⁵². The model
636 was then tuned on a curated set of ultra-widefield (200 degrees) retinal images from our cohort
637 (n = 20), each with corresponding hand-annotated VSIs. These initial wide-field vessel maps
638 were independently reviewed by a retinal specialist (SB) to ensure accuracy.

639 The generated VSIs were binarized using a threshold of 0.3 and processed to exclude any
640 small, disconnected components. As the model produces non-binary images, where each pixel
641 is assigned a probability of being a vessel, 0.3 was chosen instead of the more standard 0.5 in
642 order to detect more detail. Next, VSIs from different images of the same eye were merged
643 together in order to produce a more complete image of the retinal vasculature. Feature
644 matching for merging was performed using ORB (Oriented FAST and Rotated BRIEF) to detect
645 rotation- and scale-invariant keypoints and compute binary descriptors for efficient matching; a
646 homography was then estimated with RANSAC (Random Sample Consensus) to scale and
647 align the images without local deformation. Then, a gradient descent image registration
648 algorithm was used to find the transformation that resulted in the highest amount of overlap
649 between the vessels of the two VSI being merged by locally distorting the images. In the case of
650 more than two VSI of the same eye being merged, one VSI was chosen as the first based on
651 order of photograph capture, and additional VSI were merged on top of it sequentially. This
652 process was done per eye for each patient. When merged VSIs were available for a patient's
653 right and left eye, we extracted features from each eye independently and averaged them. If
654 only one eye's VSI was available, we used that eye's data alone; monocular imaging data was
655 used for a total of 34 patients.

656 ***Feature Generation, Categories, and Definitions***

657 We generated 99 base learners by training three different models (Logistic Regression; LR,
658 Random Forest; RF and XGboost; XGB) on 33 feature sets. These base learners were then
659 aggregated into a stacked generalization meta-learner. Base learners fall within the following
660 broad categories: graph topology, geometry, complexity/organization, nesting tree, composite,
661 and clinical features.

662 **Graph-topology base learners and features (#1-8 base learners)**

663 Graph representations of the vessel segmentations were generated by skeletonizing the binary
664 vessel segmentation images and tracking the vascular structure. Nodes were placed at points

665 where vessels bifurcated or terminated, and edges represented the vessel segments connecting
666 these nodes.

667 *Feature Set #1: Graph*

668 From each resulting graph, we extracted key structural features, including the total number of
669 nodes (encompassing both bifurcation and terminal points), the number of branching points
670 where vessels diverged, the number of terminal nodes corresponding to vessel endpoints, the
671 number of disconnected components/subgraphs, the direct distance computed as the average
672 length of an uninterrupted blood vessel segment and the mean Chebyshev distance between
673 connected nodes along each vessel segment computed as: $D_{chebyshev} =$
674 $\max(|x_1, x_2|, |y_1, y_2|)$.

675 Chebyshev distance was chosen as the baseline because the length of a vessel cannot cover
676 the distance between two points in a smaller number of pixels.

- 677 • Number of nodes: sum of number of bifurcation points and number of termination points
- 678 • Number of components: Total number of connected components in the vasculature
- 679 • Number of termination points
- 680 • Number of bifurcation points
- 681 • Average distance between nodes

682 *Feature Set #2-3: Topological Length (superior & inferior/whole graph)*

683 Topological length features were calculated using the graphs generated from the binary vessel
684 segmentation images. Two versions of topological length were computed: a simple count of
685 downstream branches until no narrower continuation was found, and a weighted version, which
686 weighs each branch by the cross sectional width of the vessel at that point. Furthermore, the
687 topological length was analyzed separately for the superior and inferior regions of the retina,
688 which is relevant because dependent, or gravitational, changes may be seen in the inferior half.

- 689 • Average topological length (weighted/unweighted)
- 690 • Median topological length (weighted/unweighted)

691 *Feature Sets #4-7: Weighted/Unweighted Superior/Inferior Topological Length Shift*

692 To assess distributional differences across all vessels – not just summary statistics (e.g.,
693 mean/median) – we computed two-sample Kolmogorov–Smirnov (KS) tests, comparing each
694 participant’s empirical distribution of topological lengths to the distribution from each healthy
695 control. The resulting KS D statistics formed a feature vector (one feature per healthy control).

696 During leave-one-out cross-validation, the held-out control's comparison was excluded to
697 prevent information leakage. KS statistics for weighted and unweighted topological length were
698 calculated for the superior and inferior vasculature.

699 *Feature Set #8: Topological Length Shift*

700 KS statistics for unweighted topological length were calculated for the whole vasculature.

701 **Geometry base learners and features (#9-15 base learners)**

702 Geometric features characterize vessel shape and layout, including branching angles, vessel
703 length, and density. Geometric features included angles, cross-sectional width of vessels, and
704 tortuosity (a blood vessel's abnormal twisting, bending, or winding path, deviating from its
705 normal straight or gently curved course).

706 *Feature Set #9: Geometry*

- 707 ● Vein density length: Sum of vessel segment lengths divided by the area of the largest
708 enclosed loop
- 709 ● Mean vein distances: Average radial distance from loop centers to their enclosing
710 vessels
- 711 ● Mean areole area: Average area enclosed by vessels (i.e., loop areas)
- 712 ● Areole density: Number of loops normalized by the area of the largest loop

713 *Feature Set #10: Angles*

714 Refers to vessel branching angles at bifurcation points

- 715 ● Average angle
- 716 ● Median angle
- 717 ● Sum angle
- 718 ● Beta (bimodality coefficient)

719 *Feature Set #11: Tortuosity*

720 Several measures of tortuosity were calculated following Hart et al.⁸⁰. Sinuosity, distance
721 inflection count tortuosity, tortuosity density, linear regression tortuosity, square curvature and
722 absolute curvature tortuosity. All tortuosity features are computed per vessel segment and
723 summarized at the subject level.

- 724 • Sinuosity: Average of all segment-level sinuosity values, where each is calculated as
725 $\Sigma(\frac{L}{D})/N$ where L is the path length that the vessel follows, D is the Chebyshev distance
726 between the two nodes at the ends of the vessel, and N is the total number of vessels.
727 (reflects the average deviation from a straight line)
- 728 • Distance inflection count tortuosity: Sinuosity, weighted by the number of inflection
729 points per vessel is calculated as $\Sigma(S*I_n)/N$ where S is the sinuosity of the vessel, I_n is
730 the number of inflection points on the vessel, and N is the total number of vessels
- 731 • Tortuosity density: Summed relative curvature between inflection points, normalized by
732 path length and averaged across vessels, calculated as $\Sigma_{vessels}(\Sigma_{inf.point}(\frac{L_{cu}}{L_{ch}}) * \frac{I-1}{L})/$
733 N where L_{cu} is the curve length between those inflection points, L_{ch} is the chord length
734 between those inflection points, I is the total number of inflection points on that vessel, L
735 is the curve length of that entire vessel, and N is the total number of vessels
- 736 • Linear regression tortuosity: The average r2 value from a linear regression performed on
737 a subset of points from each vessel is used as a measure of the linearity of the vessel,
738 as it indicates how many points on the vessel deviate from the line of best fit
- 739 • Square curvature tortuosity: Average of squared curvature values across segments,
740 highlighting accumulated turning severity, calculated as $\int (\frac{x'(t)y''(t)-x''(t)y'(t)}{(y'(t)^2+x'(t)^2)^{3/2}})^2$, which is the
741 square of the curvature of the vessel, integrated over every point in the vessel
- 742 • Absolute curvature tortuosity: Average of absolute curvature calculated as
743 $\int |\frac{x'(t)y''(t)-x''(t)y'(t)}{(y'(t)^2+x'(t)^2)^{3/2}}|$, which is the absolute value of the curvature of the vessel, integrated
744 over every point in the vessel

745 *Feature Sets #12: Vessel Thickness*

746 Vessel thickness reflects flow capacity and is calculated as the average width of each vessel.
747 Similarly to topological length, vessel thickness was analyzed separately for the superior and
748 inferior regions of the retina, which is relevant because dependent or gravitational changes may
749 be seen in the inferior half.

- 750 • Average thickness (superior/inferior)
- 751 • Median thickness (superior/inferior)

752 *Feature Sets #13-15: Superior/Inferior/Whole Vessel Thickness Shift*

753 To examine distributional differences, KS statistics were computed comparing the distribution of
754 the vessel thickness of each participant to the distributions of the healthy controls for the
755 superior, inferior, and whole vasculature. The statistic comparing to each healthy control
756 becomes a feature, such that there are as many features as healthy controls. Controls that are
757 considered test cases during LOOCV are not used to calculate features that require KS
758 statistics for the training set.

759 **Complexity/organization base learners and features (#16-21)**

760 Complexity features aim to capture the complexity of the vasculature by examining how
761 vascular structures are maintained across different scales. This is done primarily via fractal
762 dimension and the box counting vector, as well as the different topological data analysis (TDA)
763 filtrations.

764 TDA was employed to capture the geometric and structural properties of the retinal vasculature
765 across multiple spatial scales. To achieve this, we applied four distinct persistent homology
766 filtrations: Vietoris–Rips, inward radial, outward radial, and flooding. Each filtration produced a
767 corresponding persistence diagram, which was then converted into a persistence image – a
768 stable, vectorized representation of topological features across the filtration. These persistence
769 images were subjected to principal component analysis (PCA), and the first ten principal
770 components were retained as input features for downstream predictive modeling.

771 *Feature Set #16: Box Counting*

772 The box counting vector divides the image into a grid and counts how many squares in the grid
773 contain vasculature. The relationship between the scale of the grid and the number of occupied
774 squares defines the fractal dimension. The box counting vector matrix was also subjected to
775 principal component analysis (PCA), and the first ten principal components were retained as
776 input features for downstream predictive modeling.

777 *Feature Set #17: Complexity*

- 778 ● Number of loops
- 779 ● Fractal dimension

780 *Feature Set #18: TDA Outward filtration*

781 An outward radial filtration refers to a method of progressively building the vascular network
782 outward from a central point, typically the optic disc. At small radii, only vessels closest to the
783 disc are included, and as the radius increases, progressively more peripheral structures are
784 added, allowing the capture of how vessel connectivity and loops emerge and disappear as the
785 network expands. This filtration emphasizes the organization of retinal vessels radiating from

786 the center toward the periphery, making it particularly relevant for identifying structural patterns
787 that reflect normal vascular development versus pathological remodeling. Compared with the
788 complementary inward radial filtration (which grows from periphery inward), the outward radial
789 approach highlights central-to-peripheral organization and can reveal how disease states such
790 as preeclampsia, diabetes, or retinopathy alter branching, coverage, or radial distribution of
791 vessels across the retina.

792 *Feature Set #19: TDA Vietoris-Rips (VR)*

793 Points were subsampled from the vasculature binary image. Circles of increasing radius are
794 drawn around each point. Points are connected when their circles overlap. The birth and death
795 of topological features (e.g., loops, connected components) are tracked as the radius grows.

796 *Feature Set #20: TDA Inward filtration*

797 Starting from the most central point in the vascular graph, the radius of a large enclosing circle
798 is gradually reduced. As points are crossed by the circle, they are connected to other points
799 outside the circle, recreating the original graph.

800 *Feature Set #21: TDA Flooding filtration*

801 Nearby points are initially connected and then points near each complex are incorporated in it
802 as well as the radius increases. We record at what radius length features (loops and connected
803 components) appear, and at what radius they cease to exist. The difference from VR filtration is
804 that the connecting radius is projected from the edges of the simplex, not only from the points.

805 **Nesting Tree base learners and features (#22-29)**

806 A graph representation of the nesting tree was constructed to represent the hierarchical
807 structure of loops and bifurcations in the vasculature, following Katifori et al.⁵³. The nesting tree
808 is constructed by representing each loop in the vasculature as a node. Loops separated by the
809 thinnest vessels are consecutively merged, joining in the tree into a single parent node. In this
810 way, a binary tree is constructed that merges all loops. From the resulting tree, we extracted
811 multiple features that characterize the underlying vascular architecture. Features include counts,
812 ratios, and asymmetry across subtrees.

813 *Feature Sets #22-23: Nesting Number (full graph) & Nesting Num (nesting tree)*

814 The nesting ratio at each node is defined as the number of descendant nodes in the left subtree
815 divided by those in the right subtree. The resulting distribution of nesting ratios and weighted
816 nesting ratios (weighted by the total number of descendants of this node) describes local
817 asymmetry across the tree. These distributions were further summarized at the subject level into
818 global metrics: the unweighted nesting number (the average nesting ratio across nodes) and the

819 weighted nesting number (the average nesting ratio weighted by subtree size). Additionally, to
820 examine distributional differences, KS statistics were computed comparing the asymmetry
821 distribution of each participant to the distributions of the healthy controls. The statistic
822 comparing to each healthy control becomes a feature, such that there are as many features as
823 healthy controls. Controls that are considered test cases during LOOCV are not used to
824 calculate features that require KS statistics for the training set.

- 825 • Average of the nesting ratios and sum nesting ratios where nesting ratio r_n at a node n is
826 defined as:

$$827 \quad r_n = \frac{\# \text{descendants in right subtree}}{\# \text{descendants in left subtree}}$$

828 Subtree weight (w_n) is $w_n = d_n - 1$ where d_n is the subtree degree (i.e., total number of
829 descendant leaf nodes under n)

- 830 • Unweighted Nesting Number (I_u)

831 The average of all node-level nesting ratios:

$$832 \quad I_u = (1 / N) \times \sum r_n, \text{ where } N \text{ is the total number of nodes}$$

- 833 • Weighted Nesting Number (I_w)

834 The average nesting ratio, weighted by subtree size:

$$835 \quad I_w = (\sum w_n \times r_n) / (\sum w_n)$$

836 *Feature Set #24: Tree*

- 837 • Tree depth : Max branching depth of the nesting tree
- 838 • Tree leaves : Total number of leaf nodes in the nesting tree

839 *Feature Set #25: Asymmetry*

840 Tree asymmetry measures the imbalance in the number of branches between descendant
841 nodes across all bifurcations, computed per node and summarized over subtrees of size δ
842 within a window Δ . Asymmetry at a node (a_n) is defined as:

$$843 \quad a_n = |L_n - R_n| / (L_n + R_n)$$

844 where L_n and R_n are the number of nodes in the left and right subtrees of node n , respectively,
845 and the average asymmetry across subtrees of size δ is computed as:

$$846 \quad \bar{a}(\delta, \Delta) = (1 / |N\delta|) \times \sum a_n$$

847 where $N\delta$ is the set of nodes with subtree size within $\Delta/2$ of δ .

- 848 • Average asymmetry, sum asymmetry, asymmetry quartiles: Aggregated branching
849 asymmetry, based on average asymmetry per subtree of size δ

850 *Feature Set #26: Asymmetry Shift*

851 KS statistics for asymmetry were calculated.

852 *Feature Set #27: Cumulative Size Distribution*

853 Measures how the areas of enclosed loops in the blood vessel network are distributed. From the
854 set of enclosed loop areas $\{a_1, a_2, \dots, a_N\}$ extracted from the nesting tree, the cumulative
855 proportion $P(a)$ of loops with area less than or equal to a is computed as:

$$856 \quad P(a) = \frac{\text{Number of loops with area } \leq a}{\text{Total number of loops } (N)}$$

- 857 • Average cumulative size distributions, sum cumulative size distributions, cumulative size
858 distribution quartiles : Summary statistics of cumulative proportion $P(a)$

859 *Feature Set #28: Strahler order features*

860 Strahler order quantifies the branching hierarchy by assigning an order of 1 to terminal
861 branches. When two branches of the same order merge, the resulting branch is assigned an
862 order one higher; if the merging branches have different orders, the resulting branch takes the
863 maximum of the two. This metric reflects the structural complexity and depth of the vascular
864 network. Bifurcation ratio captures the branching pattern by comparing the consecutive Strahler
865 orders.

- 866 • Strahler order counts 1 to 5: Number of nodes with a given Strahler branching level,
867 which represents how many branching points away that node is from a leaf node

868 *Feature Set #29 : bifurcation ratio features*

869 The bifurcation ratio features indicate the ratio of the number of nodes of a particular Strahler
870 order to the number of nodes of the next Strahler order.

- 871 • Bifurcation ratio 2 to 3: Ratio of Strahler orders between levels (i.e. bifurcation level n
872 represents Strahler-order n / Strahler order $n+1$)

873 **Composite base learners and features (#30-32)**

874 *Feature Set #30: Ratio*

875 Ratios that compare vascular characteristics between superior and inferior regions of the retinal
876 image. Specifically, it includes the average and median of the superior-to-inferior ratios for
877 topological length and for vessel thickness, calculated using both weighted and unweighted
878 measurements.

- 879 ● Average or median of superior-to-inferior ratio of topological length (both weighted and
880 unweighted)
- 881 ● Average or median of superior-to-inferior ratio of vessel thickness

882 *Feature Set #31: Standard Deviation*

883 The standard deviation of the vascular features to capture variability within each image:

- 884 ● Cumulative size distribution
- 885 ● Topological length (superior/inferior and weighted/unweighted)
- 886 ● Vessel thickness (superior/inferior)
- 887 ● Nesting ratio (weighted/unweighted)
- 888 ● Angles

889 *Feature Set #32: Mixed*

890 Includes several features from different base learners described above to allow for interaction
891 effects among predictive base learners.

- 892 ● Number of branches
- 893 ● Distance between branches
- 894 ● Square curvature tortuosity
- 895 ● Number of loops
- 896 ● Fractal dimension
- 897 ● Average topological lengths (superior/inferior)

898 **Clinical base learner and features (#33)**

899 *Feature Set #33: Clinical*

900 Clinical features included maternal demographic characteristics, reproductive history, and
901 preexisting or pregnancy-related morbidities. Specifically, we extracted data on maternal age,
902 race and ethnicity, smoking status, and use of in vitro fertilization (IVF). We also recorded
903 indicators of maternal risk, including advanced maternal age (AMA), prior history of

904 hypertension, diabetes, or preeclampsia, as well as use of low-dose aspirin during pregnancy.
905 These features comprised the clinical feature set used in downstream analyses.

906 **FMF benchmark model**

907 We additionally trained a model based on the FMF algorithm²⁷. This model includes features
908 used by the FMF algorithm: maternal age, smoking status, prior history of preeclampsia or
909 preterm labor, use of IVF, diabetes status (as well as type and medication), maternal race and
910 ethnicity, nulliparous status, as well as preexisting hypertension. Due to lack of availability, we
911 did not include maternal height or weight, last menstrual period and estimated delivery date, as
912 well as limited other maternal medical history, such as vanishing twin syndrome, family history
913 of preeclampsia, systemic lupus erythematosus, anti-phospholipid syndrome, inter-pregnancy
914 period, gestational age at delivery and birth weight for last pregnancy. Available features were
915 used to train a logistic regression, random forest, and XGBoost model, and the highest
916 performing model was selected.

917 **Capturing distributional differences using the Kolmogorov-Smirnov (KS) Test Statistics**

918 Some features, such as topological length or asymmetry, generate a value per blood vessel
919 segment, resulting in a distribution for each subject. To incorporate these in our models, we first
920 extracted summary statistics such as the median value or the quartiles. Additionally, we used
921 Kolmogorov-Smirnov (KS) statistics to capture distributional differences: for each subject, we
922 compared their distribution to that of a reference healthy control group. The KS statistic
923 quantifies the maximum difference between the cumulative distribution functions (CDFs) of the
924 two groups, with a value of 0 indicating identical distributions and higher values indicating
925 greater divergence, effectively measuring how much a participant's vessel-level feature
926 distribution deviates from that of healthy controls. This method generates a feature per control.
927 This resulting matrix undergoes a PCA decomposition, and the first ten principal components
928 were used as the predictive features.

929 **Cohort Stratification**

930 Cases were predicted against different control or non-cases groups to ascertain if the captured
931 signal is a general disease signal (case vs healthy control), or a signature specific to
932 preeclampsia (case vs non-case/population-wide).

933 The healthy control group excluded individuals with any maternal comorbidities, pregnancy
934 complications, or ocular conditions, including cardiometabolic, neurologic, vascular,
935 hematologic, endocrine, infectious, or genetic diseases; multifetal gestation; ocular surgery or
936 trauma; medication use (e.g., blood pressure medications, insulin, or aspirin); and pregnancies

937 affected by hypertensive disorders, gestational diabetes, cholestasis, HELLP, hyperemesis,
938 stillbirth, multiple pregnancy (e.g., twins/triplets), or smoking.

939 For the population-wide control group, we relaxed our criteria to only exclude the following
940 conditions relevant to hypertensive disorders of pregnancy: multiple pregnancy (e.g.,
941 twins/triplets), gestational hypertension, HELLP syndrome, and stillbirth.

942 **Predictive Model**

943 A stacked Ensemble Model is used to integrate multiple feature sets representing diverse
944 aspects of the retinal vasculature. This stacking approach improves classification accuracy by
945 leveraging the complementary strengths of the individual models.

946 First, base learners were constructed by training three classifiers – Logistic Regression (LR),
947 Random Forest (RF), and XGBoost (XGB) – on each feature set. Leave-one-out cross-
948 validation (LOOCV) was used to optimize the hyperparameters for each base learner (LR –
949 penalty: L1, L2; C: 0.01, 0.1, 1.0, 10; solver: saga. RF – number of estimators: 100, 200;
950 max_depth: 1, 3, None; min_samples_leaf: 1, 2; min_samples_split: 2, 5; max_features: sqrt,
951 0.5, None. XGB – number of estimators: 100, 250; max depth: 1, 2, 3; learning rate: 0.01, 0.1,
952 0.3; subsample: 0.8, 1.0; scale positive weight: 2,8,12), with the best combination selected
953 based on F1 score. Base learners with AUC less than or equal to 0.5 were eliminated from
954 meta-learner consideration.

955 The out-of-fold predictions from the base learners were used to train an XGB meta-learner with
956 recursive feature elimination (RFE) for base learner selection. Similar to the base learners, the
957 meta-learner had its hyperparameters (number of estimators: 100, 250; max depth: 1, 2, 3;
958 learning rate: 0.01, 0.1, 0.3; subsample: 0.8, 1.0; scale positive weight: 2, 8, 12; number of base
959 learners to select with RFE: 8, 16, 32), tuned using LOOCV to prioritize F1 scores.

960 The healthy control ensemble model was trained on the preeclampsia cases (n = 54) and
961 healthy controls (n = 82). This model serves to help inspect signals discriminating between
962 cases and controls because the greatest difference is expected when comparing to a healthy
963 cohort based on univariate analysis.

964 Each population-wide ensemble model was trained on the preeclampsia cases (n = 54), healthy
965 controls (n = 82), and 10 different sets of population-wide non-healthy controls (10 times;
966 n≥100). Performance metrics (FPR, TPR, PPV, NPV) were calculated per model and averaged.
967 The 95% confidence intervals were determined using the standard error of the mean. This
968 method, utilizing several population-wide sets instead of upsampling cases, was selected to
969 specifically mitigate the chance of overfitting due to the low prevalence of preeclampsia. By

970 performing LOOCV across 10 sets with distinct population-wide non-health controls, the
971 confidence intervals serve as a measure of model generalizability.

972 For interpretability, the SHAP values are calculated for each held-out patient. Each patient's
973 vector of SHAP values was normalized per prediction and averaged across models for
974 population-wide ensemble models. To calculate category SHAP, the base learner normalized
975 and averaged SHAP values were summed per patient. Base learner selection for the meta-
976 learners is inherently reflected in the SHAP values, with RFE excluded base learners having a
977 SHAP value of 0.

978 **Univariate Analysis**

979 The extracted features were analyzed in a univariate way to identify how individual features are
980 affected by the disease. For each feature, the following analyses were conducted: Mann-
981 Whitney U test, KS test, odds ratio, fold-change risk ratio, and logistic regression.

982 The Mann-Whitney U test is a non-parametric test used to test if for a given feature that case
983 and control populations share the same distribution. Similarly, the KS test is also a non-
984 parametric test used to test if case and control populations share the same distribution. It
985 evaluates any difference in distribution, whereas the Mann-Whitney U test evaluates if there is a
986 shift in the median.

987 **Data availability**

988 Following publication in a peer-reviewed journal, we will make a curated, de-identified dataset
989 publicly available through a secure data repository, in full compliance with applicable data
990 sharing policies, institutional requirements, and ethical guidelines, including those governing
991 human subjects research. Access will be provided in a manner consistent with participant
992 confidentiality and regulatory standards. Summary-level data supporting the key findings are
993 included in the main text and Supplementary Information.

994 **Funding**

995 SB is supported by the Columbia University Irving Institute for Clinical and Translational
996 Research (CTSA Grant UL1TR001873), the Dalio Center for Health Justice at NewYork-
997 Presbyterian, and the New York Community Trust – Frederick J. and Theresa Dow Wallace
998 Fund (administered through Columbia University and NewYork-Presbyterian). LS, CA, DS, are
999 supported by Burroughs Wellcome Fund (CASI award G-1022553).

1000 **Acknowledgments**

1001 We thank Sabine Bousleiman, Noelle Pensec, David Wentsler, Yessenia Gutierrez, Zoilo
1002 Castillo, Jose Castillo Camacho, Casandra Almonte, Cynthia Masson, Alexa Kaminsky, Andrea

1003 P Moscoso, Ruddys Pena Recio, Emely Carmona Reyes, Desiree Torres, Stefania Maruri,
1004 Kaveri Thakoor, Ye Tian for their invaluable contributions for this work.


1005 **Supplementary Materials**

Table S1	Characteristics of the study population
Figure S1	Clinical, retinal, and all feature performance predicting Preeclampsia with Healthy Controls (AUC, AP, TPR, PPV, NPV, and SHAP summary).
Figure S2	Retinal base learner SHAP values for predicting Preeclampsia with Population-Wide Controls.
Figure S3	Retinal base learner SHAP values for predicting Preeclampsia with Healthy Controls.
Figure S4	EOPE-specific univariate distributions.
Figure S5	Retinal base learner SHAP values for predicting GHTN with Population-Wide Controls.
Figure S6	Retinal base learner SHAP values for predicting CHTN with Population-Wide Controls.

Table 1: Characteristics of the Study Population

Variables	Cohort (n=1267)	Population-Wide (n=1083)	Healthy Controls (n=82)	PEC (n=55)	SF (n=38)	NSF (n=17)	EOPE (n=20)	LOPE (n=35)	GHTN (n=49)
Maternal age, years (mean ± SD)	29.91 ± 6.04	29.76 ± 6.04	28.70 ± 5.73	30.40 ± 6.87	31.87 ± 6.41	27.12 ± 6.91	32.15 ± 7.69	29.40 ± 6.26	30.55 ± 5.87
Maternal ethnicity, Hispanic or Latinx (%)	1076 (84.9%)	921 (85.0%)	73 (89.0%)	46 (83.6%)	31 (81.6%)	15 (88.2%)	15 (75.0%)	31 (88.6%)	40 (81.6%)
Obesity (%)	445 (35.1%)	357 (33.0%)	0 (0.0%)	22 (40.0%)	15 (39.5%)	7 (41.2%)	9 (45.0%)	13 (37.1%)	32 (65.3%)*
PEC history (%)	67 (5.3%)	41 (3.8%)	1 (1.2%)	9 (16.4%)*	6 (15.8%)*	3 (17.6%)*	3 (15.0%)*	6 (17.1%)*	7 (14.3%)*
Chronic hypertension (%)	71 (5.6%)	38 (3.5%)	0 (0.0%)	10 (18.2%)*	9 (23.7%)*	1 (5.9%)	4 (20.0%)*	6 (17.1%)*	3 (6.1%)
Smoking status (%)	124 (9.8%)	98 (9.0%)	3 (3.7%)	9 (16.4%)	7 (18.4%)	2 (11.8%)	2 (10.0%)	7 (20.0%)	7 (14.3%)
Endocrine Disease (%)	113 (8.9%)	85 (7.8%)	0 (0.0%)	8 (14.5%)	6 (15.8%)	2 (11.8%)	5 (25.0%)*	3 (8.6%)	9 (18.4%)*
Conception by IVF (%)	17 (1.3%)	11 (1.0%)	2 (2.4%)	4 (7.3%)*	4 (10.5%)*	0 (0.0%)	1 (5.0%)	3 (8.6%)*	0 (0.0%)
Nulliparous (%)	484 (38.2%)	398 (36.7%)	35 (42.7%)	30 (54.5%)*	18 (47.4%)	12 (70.6%)*	10 (50.0%)	20 (57.1%)*	25 (51.0%)


Table 1. Characteristics of the study population. Clinical characteristics of study participants are presented across key population subsets and preeclampsia subtypes. The cohort-wide column includes all enrolled individuals. Population-wide controls refer to participants without major pregnancy complications in current pregnancy, excluding those with multiple gestations (e.g., twins/triplets), gestational hypertension, or stillbirth. Healthy controls represent a more stringently defined subcohort, excluding any maternal comorbidities, pregnancy complications, or ocular conditions; they comprise a subset of the 176 healthy controls identified within the full cohort. There is a subset of 80 participants who are not HDP cases but were excluded from the control group due to one or more of the following: multiple pregnancy (e.g., twins/triplets), stillbirth or a lack of usable images. *PEC* (preeclampsia); *SF* (severe features); *NSF* (no severe features); *EOPE* (early onset preeclampsia); *LOPE* (late onset preeclampsia), *GHTN* (gestational hypertension). Comparisons tested using Mann-Whitney U test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.



1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016


Supplementary Figure 1. Visionary AI performance predicting Preeclampsia with Healthy Controls
(A) ROC curves, PR curves, and retinal model SHAP distributions by category and key base learners for different preeclampsia subgroups. The retinal model outperforms the clinical model in all cases. The all model, which combines both retinal and clinical features performs the best. The EOPE ROC and PR plots include curves for a model trained specifically for EOPE detection from retinal features. **(B)** ROC along with average Precision (PPV), NPV, and TPR values are shown for retinal model in barplots with a threshold of 0.5. FPR for all subsets of 0.11. **(C)** SHAP values for key feature categories and top five base learners based on average absolute SHAP value, labeled with relevant biological processes. *PEC* (preeclampsia); *SF* (severe features); *NSF* (no severe features); *EOPE* (early onset preeclampsia); *LOPE* (late onset preeclampsia).

1017



1018

1019 **Supplementary Figure 2. Visionary AI base learner SHAP values for predicting Preeclampsia with**
1020 **Population-Wide Controls** For each population-wide model, SHAP values were calculated for each
1021 patient. These SHAP vectors were normalized and averaged by patient across models. The base learners
1022 are sorted by average absolute SHAP value.



1023

1024

1025


1026

1027

1028

1029


Supplementary Figure 3. Visionary AI base learner SHAP values for predicting Preeclampsia with Healthy Controls SHAP values were calculated for each patient. These SHAP vectors were normalized by patient. The base learners are sorted by average absolute SHAP value.



1030

1031 **Supplementary Figure 4. Features distinguishing early- and late-onset preeclampsia (EOPE vs.**
1032 **LOPE).** Univariate analyses were performed to compare EOPE with both healthy and population-wide
1033 controls. These boxplots highlight features that are significantly associated with EOPE and illustrate how
1034 these patterns differ from those observed in LOPE. Together, they underscore the distinct vascular
1035 complexity and remodeling profiles of EOPE compared to other groups. *HC (healthy controls); PW*
1036 *(population-wide controls); EOPE (early-onset preeclampsia); LOPE (late-onset preeclampsia); PEC*
1037 *(preeclampsia); Comparisons tested using Mann-Whitney U test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.*

1038



1039


1040

1041

1042

1043

Supplementary Figure 5. Visionary AI base learner SHAP values for predicting GHTN with Population-Wide Controls For each population-wide model, SHAP values were calculated for each patient. These SHAP vectors were normalized and averaged by patient across models. The base learners are sorted by average absolute SHAP value.



1044

1045 **Supplementary Figure 6. Visionary AI base learner SHAP values for predicting CHTN with**
1046 **Population-Wide Controls** For each population-wide model, SHAP values were calculated for each
1047 patient. These SHAP vectors were normalized and averaged by patient across models. The base learners
1048 are sorted by average absolute SHAP value.

1049

1050

1051

1052

1053

1054 **References**

- 1055 1. Say, L. *et al.* Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health* **2**,
1056 e323-33 (2014).
- 1057 2. Lo, J. O., Mission, J. F. & Caughey, A. B. Hypertensive disease of pregnancy and maternal
1058 mortality. *Curr Opin Obstet Gynecol* **25**, 124–132 (2013).
- 1059 3. Chappell, L. C., Cluver, C. A., Kingdom, J. & Tong, S. Pre-eclampsia. *Lancet* **398**, 341–354 (2021).
- 1060 4. Bushnell, C. & Chireau, M. Preeclampsia and Stroke: Risks during and after Pregnancy. *Stroke Res*
1061 *Treat* **2011**, 858134 (2011).
- 1062 5. Davis, M. B. *et al.* Team-Based Care of Women With Cardiovascular Disease From Pre-Conception
1063 Through Pregnancy and Postpartum: JACC Focus Seminar 1/5. *Journal of the American College of*
1064 *Cardiology* **77**, (2021).
- 1065 6. Samara, A. A. *et al.* Preeclampsia, gestational hypertension and incident dementia: A systematic
1066 review and meta-analysis of published evidence. *Pregnancy hypertension* **30**, (2022).
- 1067 7. Koulouraki, S. *et al.* Short- and Long-Term Outcomes of Preeclampsia in Offspring: Review of the
1068 Literature. *Children (Basel)* **10**, (2023).
- 1069 8. American College of Obstetricians and Gynecologists & Task Force on Hypertension in Pregnancy.
1070 Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task
1071 force on hypertension in pregnancy. *Obstet. Gynecol.* **122**, 1122–1131 (2013).
- 1072 9. Than, N. G. *et al.* Integrated systems biology approach identifies novel maternal and placental
1073 pathways of preeclampsia. *Front. Immunol.* **9**, 1661 (2018).
- 1074 10. Than, N. G. *et al.* Classification of preeclampsia according to molecular clusters with the goal of
1075 achieving personalized prevention. *J. Reprod. Immunol.* **161**, 104172 (2024).
- 1076 11. Walsh, S. W. & Strauss, J. F. The Road to Low-Dose Aspirin Therapy for the Prevention of
1077 Preeclampsia Began with the Placenta. *International journal of molecular sciences* **22**, (2021).
- 1078 12. Brosens, I., Pijnenborg, R., Vercruyse, L. & Romero, R. The “Great Obstetrical Syndromes” are
1079 associated with disorders of deep placentation. *Am J Obstet Gynecol* **204**, 193–201 (2011).
- 1080 13. Kulkarni, V. G. *et al.* Maternal and fetal vascular lesions of malperfusion in the placentas associated
1081 with fetal and neonatal death: results of a prospective observational study. *Am J Obstet Gynecol* **225**,
1082 660.e1-660.e12 (2021).
- 1083 14. Ahmed, I. *et al.* Placental inflammation and pregnancy outcomes: A prospective, observational
1084 study in South Asia: The PURPOSE study. *BJOG* **130 Suppl 3**, 43–52 (2023).
- 1085 15. Miller, D. *et al.* Cellular immune responses in the pathophysiology of preeclampsia. *Journal of*
1086 *leukocyte biology* **111**, (2022).
- 1087 16. Jung, E. *et al.* The etiology of preeclampsia. *American journal of obstetrics and gynecology* **226**,
1088 S844 (2022).
- 1089 17. Stevens, W. *et al.* Short-term costs of preeclampsia to the United States health care system. *Am J*
1090 *Obstet Gynecol* **217**, 237-248.e16 (2017).
- 1091 18. Cameron, N. A. *et al.* Trends in the Incidence of New-Onset Hypertensive Disorders of Pregnancy
1092 Among Rural and Urban Areas in the United States, 2007 to 2019. *J Am Heart Assoc* **11**, e023791
1093 (2022).
- 1094 19. Bruno, A. M., Allshouse, A. A., Metz, T. D. & Theilen, L. H. Trends in Hypertensive Disorders of
1095 Pregnancy in the United States From 1989 to 2020. *Obstet Gynecol* **140**, 83–86 (2022).
- 1096 20. Phibbs, C. S. *et al.* Birth Hospitalization Costs and Days of Care for Mothers and Neonates in
1097 California, 2009-2011. *J Pediatr* **204**, 118-125.e14 (2019).
- 1098 21. Hao, J. *et al.* Maternal and Infant Health Care Costs Related to Preeclampsia. *Obstet Gynecol* **134**,
1099 1227–1233 (2019).
- 1100 22. Rolnik, D. L., Wright, D. & Poon, L. C. Aspirin versus Placebo in Pregnancies at High Risk for
1101 Preterm Preeclampsia. *N Engl J Med* **377**, 613–622 (2017).
- 1102 23. Hoffman, M. K. The great obstetrical syndromes and the placenta. *BJOG* **130 Suppl 3**, 8–15 (2023).
- 1103 24. US Preventive Services Task Force *et al.* Screening for Hypertensive Disorders of Pregnancy: US

- 1104 Preventive Services Task Force Final Recommendation Statement. *JAMA* **330**, 1074–1082 (2023).
- 1105 25. Feng, W. & Luo, Y. Preeclampsia and its prediction: traditional versus contemporary predictive
- 1106 methods. *J. Matern. Fetal. Neonatal Med.* **37**, 2388171 (2024).
- 1107 26. Zeisler, H. *et al.* Predictive value of the sFlt-1:PIGF ratio in women with suspected preeclampsia. *N.*
- 1108 *Engl. J. Med.* **374**, 13–22 (2016).
- 1109 27. Ontario Health (Quality). First-Trimester Screening Program for the Risk of Pre-eclampsia Using a
- 1110 Multiple-Marker Algorithm: A Health Technology Assessment. *Ontario Health Technology*
- 1111 *Assessment Series* **22**, 1 (2022).
- 1112 28. O’Gorman, N. *et al.* Multicenter screening for pre-eclampsia by maternal factors and biomarkers at
- 1113 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations.
- 1114 *Ultrasound Obstet Gynecol* **49**, 756–760 (2017).
- 1115 29. De Kat, A. C., Hirst, J., Woodward, M., Kennedy, S. & Peters, S. A. Prediction models for
- 1116 preeclampsia: A systematic review. *Pregnancy Hypertens.* **16**, 48–66 (2019).
- 1117 30. Silverman, R. H., Urs, R., Wapner, R. J. & Bearely, S. Plane-Wave Ultrasound Doppler of the Eye
- 1118 in Preeclampsia. *Translational vision science & technology* **9**, (2020).
- 1119 31. Silverman, R. H. *et al.* Correlation of Ocular Plane-Wave Doppler With Optical Coherence
- 1120 Tomography Angiography in Preeclampsia. *Journal of ultrasound in medicine : official journal of*
- 1121 *the American Institute of Ultrasound in Medicine* **42**, (2023).
- 1122 32. Jaffe, G. & Schatz, H. Ocular manifestations of preeclampsia. *American journal of ophthalmology*
- 1123 **103**, (1987).
- 1124 33. Stern-Ascher, C. N. *et al.* Subfoveal choroidal thickness and associated changes of angiogenic
- 1125 factors in women with severe preeclampsia. *Am. J. Perinatol.* **38**, 482–489 (2021).
- 1126 34. Garg, A. *et al.* Choroidal and retinal thickening in severe preeclampsia. *Investigative ophthalmology*
- 1127 *& visual science* **55**, (2014).
- 1128 35. Auger, N. *et al.* Preeclampsia and Long-term Risk of Maternal Retinal Disorders. *Obstetrics and*
- 1129 *gynecology* **129**, (2017).
- 1130 36. Lee, J., Bae, J. G. & Kim, Y. C. Relationship between the sFlt-1/PIGF ratio and the optical
- 1131 coherence tomographic features of choroid retina in patients with preeclampsia. *PloS one* **16**, (2021).
- 1132 37. Ciccone L, Rodriguez Coleman H, Wapner RJ, Ananth C, Bearely S. Infero-temporal retinal artery
- 1133 tortuosity differs between severe preeclampsia and normotensive controls in the immediate post-
- 1134 partum period. Presented at *Women in Ophthalmology Annual Meeting*, Coeur D’Alene, Idaho,
- 1135 August 2019.
- 1136 38. He, Y. *et al.* Changes in Optical Coherence Tomography Angiography Precede Clinical Onset of
- 1137 Placental Insufficiency. *Invest Ophthalmol Vis Sci* **66**, 36 (2025).
- 1138 39. Lupton, S. J. *et al.* Changes in retinal microvascular caliber precede the clinical onset of
- 1139 preeclampsia. *Hypertension* **62**, 899–904 (2013).
- 1140 40. Ciloglu, E., Okcu, N. T. & Dogan, N. Ç. Optical coherence tomography angiography findings in
- 1141 preeclampsia. *Eye (Lond)* **33**, 1946–1951 (2019).
- 1142 41. Poplin, R. *et al.* Prediction of cardiovascular risk factors from retinal fundus photographs via deep
- 1143 learning. *Nat Biomed Eng* **2**, 158–164 (2018).
- 1144 42. Zhang, L. *et al.* Prediction of hypertension, hyperglycemia and dyslipidemia from retinal fundus
- 1145 photographs via deep learning: A cross-sectional study of chronic diseases in central China. *PLoS*
- 1146 *One* **15**, e0233166 (2020).
- 1147 43. Ding Y. D. *et al.* [A deep-learning model for the assessment of coronary heart disease and related
- 1148 risk factors via the evaluation of retinal fundus photographs]. *Zhonghua Xin Xue Guan Bing Za Zhi*
- 1149 **50**, 1201–1206 (2022).
- 1150 44. Rom, Y. *et al.* Diabetes detection from non-diabetic retinopathy fundus images using deep learning
- 1151 methodology. *Heliyon* **10**, e36592 (2024).
- 1152 45. Wu, Y. *et al.* Noninvasive early prediction of preeclampsia in pregnancy using retinal vascular
- 1153 features. *NPJ Digit Med* **8**, 188 (2025).
- 1154 46. Zhou, T. *et al.* Prediction of preeclampsia from retinal fundus images via deep learning in singleton

- 1155 pregnancies: a prospective cohort study. *J Hypertens* **42**, 701–710 (2024).
- 1156 47. Kamran, S. A. *et al.* RV-GAN: Segmenting Retinal Vascular Structure in Fundus Photographs
1157 Using a Novel Multi-scale Generative Adversarial Network. *Medical Image Computing and*
1158 *Computer Assisted Intervention – MICCAI 2021* 34–44 (2021).
- 1159 48. Staal, J., Abràmoff, M. D., Niemeijer, M., Viergever, M. A. & van Ginneken, B. Ridge-based vessel
1160 segmentation in color images of the retina. *IEEE Trans Med Imaging* **23**, 501–509 (2004).
- 1161 49. Hoover, A., Kouznetsova, V. & Goldbaum, M. Locating blood vessels in retinal images by
1162 piecewise threshold probing of a matched filter response. *IEEE Trans Med Imaging* **19**, 203–210
1163 (2000).
- 1164 50. Fraz, M. M. *et al.* An ensemble classification-based approach applied to retinal blood vessel
1165 segmentation. *IEEE Trans Biomed Eng* **59**, 2538–2548 (2012).
- 1166 51. Budai, A., Bock, R., Maier, A., Hornegger, J. & Michelson, G. Robust vessel segmentation in
1167 fundus images. *Int J Biomed Imaging* **2013**, 154860 (2013).
- 1168 52. Zhang, J. *et al.* Robust Retinal Vessel Segmentation via Locally Adaptive Derivative Frames in
1169 Orientation Scores. *IEEE Trans Med Imaging* **35**, 2631–2644 (2016).
- 1170 53. Katifori, E. & Magnasco, M. O. Quantifying loopy network architectures. *PLoS One* **7**, e37994
1171 (2012).
- 1172 54. Geroldinger, A., Lusa, L., Nold, M. & Heinze, G. Leave-one-out cross-validation, penalization, and
1173 differential bias of some prediction model performance measures—a simulation study. *Diagn Progn*
1174 *Res* **7**, 9 (2023).
- 1175 55. Bradshaw, T. J., Huemann, Z., Hu, J. & Rahmim, A. A Guide to Cross-Validation for Artificial
1176 Intelligence in Medical Imaging. *Radiol Artif Intell* **5**, e220232 (2023).
- 1177 56. Tan, M. Y. *et al.* Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’
1178 gestation. *Ultrasound Obstet Gynecol* **52**, 186–195 (2018).
- 1179 57. Lundberg, S. M. & Lee, S.-I. A Unified Approach to Interpreting Model Predictions. in *Advances in*
1180 *Neural Information Processing Systems* (eds. Guyon, I. *et al.*) vol. 30 4765–4774 (Curran
1181 Associates, Inc., 2017).
- 1182 58. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. *Nature*
1183 **473**, 298 (2011).
- 1184 59. The Multifractal Structure of Arterial Trees. *Journal of Theoretical Biology* **220**, 75–82 (2003).
- 1185 60. Han, H.-C. Twisted blood vessels: symptoms, etiology and biomechanical mechanisms. *J Vasc Res*
1186 **49**, 185–197 (2012).
- 1187 61. Fumoto, T., Kinoshita, S., Sasaki, T., Shimamura, N. & Ohkuma, H. Oxidative Stress Mediates
1188 Vascular Tortuosity. *Antioxidants (Basel)* **10**, (2021).
- 1189 62. Boone, M. I., Farber, M. E., Jovanovic-Peterson, L. & Peterson, C. M. Increased retinal vascular
1190 tortuosity in gestational diabetes mellitus. *Ophthalmology* **96**, 251–254 (1989).
- 1191 63. Ghodasra, D. H. *et al.* The rate of change in retinal vessel width and tortuosity in eyes at risk for
1192 retinopathy of prematurity. *J AAPOS* **16**, 431–436 (2012).
- 1193 64. Tianfan, Z. *et al.* Feasibility study on quantifying retinal vascular features for predicting
1194 preeclampsia based on artificial intelligence models. *Journal of Shanghai Jiao Tong University*
1195 *(Medical Science)* **44**, 552 (2024).
- 1196 65. Gerhardt, H. *et al.* VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *The*
1197 *Journal of cell biology* **161**, (2003).
- 1198 66. De Smet, F., Segura, I., De Bock, K., Hohensinner, P. J. & Carmeliet, P. Mechanisms of vessel
1199 branching: filopodia on endothelial tip cells lead the way. *Arteriosclerosis, thrombosis, and vascular*
1200 *biology* **29**, (2009).
- 1201 67. Blanco, R. & Gerhardt, H. VEGF and Notch in tip and stalk cell selection. *Cold Spring Harb*
1202 *Perspect Med* **3**, a006569 (2013).
- 1203 68. Foidart, J. M., Schaaps, J. P., Chantraine, F., Munaut, C. & Lorquet, S. Dysregulation of anti-
1204 angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia—a step forward but not the
1205 definitive answer. *J Reprod Immunol* **82**, 106–111 (2009).

- 1206 69. Renna, N. F., de Las Heras, N. & Miatello, R. M. Pathophysiology of vascular remodeling in
1207 hypertension. *Int J Hypertens* **2013**, 808353 (2013).
- 1208 70. Chen, W. *et al.* The endothelial tip-stalk cell selection and shuffling during angiogenesis. *J Cell*
1209 *Commun Signal* **13**, 291–301 (2019).
- 1210 71. Nama, V., Manyonda, I. T., Onwude, J. & Antonios, T. F. Structural capillary rarefaction and the
1211 onset of preeclampsia. *Obstet Gynecol* **119**, 967–974 (2012).
- 1212 72. Schwartz, K. S. & Stanhewicz, A. E. Maternal Microvascular Dysfunction During and After
1213 Preeclamptic Pregnancy. *Compr Physiol* **14**, 5703–5727 (2024).
- 1214 73. Catov, J. M. *et al.* Maternal Vascular Lesions in the Placenta Predict Vascular Impairments a
1215 Decade After Delivery. *Hypertension* **79**, 424–434 (2022).
- 1216 74. Bakrania, B. A. *et al.* Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and
1217 Vascular Dysfunction. *Compr Physiol* **11**, 1315–1349 (2020).
- 1218 75. Antonios, T. F. T., Nama, V., Wang, D. & Manyonda, I. T. Microvascular remodelling in
1219 preeclampsia: quantifying capillary rarefaction accurately and independently predicts preeclampsia.
1220 *Am J Hypertens* **26**, 1162–1169 (2013).
- 1221 76. Krielessi, V. *et al.* Placental Pathology and Blood Pressure's Level in Women with Hypertensive
1222 Disorders in Pregnancy. *Obstet Gynecol Int* **2012**, 684083 (2012).
- 1223 77. Zhang, P. Decidual Vasculopathy in Preeclampsia and Spiral Artery Remodeling Revisited: Shallow
1224 Invasion versus Failure of Involution. *AJP Rep* **8**, e241–e246 (2018).
- 1225 78. Tomita, R. *et al.* Differences in Blood Flow Between Superior and Inferior Retinal Hemispheres.
1226 *Invest Ophthalmol Vis Sci* **61**, 27 (2020).
- 1227 79. Yee Khong, T., Mooney, E. E., Nikkels, P. G. J., Morgan, T. K. & Gordijn, S. J. *Pathology of the*
1228 *Placenta: A Practical Guide*. (Springer, 2018).
- 1229 80. Hart, W. E., Goldbaum, M., Côté, B., Kube, P. & Nelson, M. R. Measurement and classification of
1230 retinal vascular tortuosity. *Int J Med Inform* **53**, 239–252 (1999).